Open AccessTherapy response prediction in major depressive disorder: current and novel genomic markers influencing pharmacokinetics and pharmacodynamics
Author(s) -
Alena A. Shalimova,
Viktoria Babasieva,
Vladimir N. Chubarev,
Vadim V. Tarasov,
Helgi B. Schiöth,
Jessica Mwinyi
Publication year - 2021
Publication title -
pharmacogenomics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.541
H-Index - 91
eISSN - 1744-8042
pISSN - 1462-2416
DOI - 10.2217/pgs-2020-0157
Subject(s) - pharmacogenetics , pharmacodynamics , medicine , pharmacogenomics , cyp2c19 , cyp2d6 , major depressive disorder , clinical significance , genome wide association study , pharmacokinetics , disease , pharmacotherapy , bioinformatics , oncology , pharmacology , clinical psychology , biology , gene , single nucleotide polymorphism , genetics , genotype , cytochrome p450 , metabolism , mood
Major depressive disorder is connected with high rates of functional disability and mortality. About a third of the patients are at risk of therapy failure. Several pharmacogenetic markers especially located in CYP450 genes such as CYP2D6 or CYP2C19 are of relevance for therapy outcome prediction in major depressive disorder but a further optimization of predictive tools is warranted. The article summarizes the current knowledge on pharmacogenetic variants, therapy effects and side effects of important antidepressive therapeutics, and sheds light on new methodological approaches for therapy response estimation based on genetic markers with relevance for pharmacokinetics, pharmacodynamics and disease pathology identified in genome-wide association study analyses, highlighting polygenic risk score analysis as a tool for further optimization of individualized therapy outcome prediction.